Circassia Group PLC represents core values of innovation, collaboration, and patient-centered care. With a strong corporate philosophy focused on improving the lives of patients, Circassia aims to develop and commercialize innovative medical solutions. By fostering collaborations with key partners, the company strives to accelerate research and bring cutting-edge therapies to address unmet medical needs. Circassia's commitment to patient-centered care ensures that their products are designed to provide optimal outcomes and enhance the quality of life for patients. Through its dedication to innovation, collaboration, and patient-focused solutions, Circassia Group PLC stands as a leading player in the healthcare industry.

Circassia Group PLC is primarily present in the United Kingdom.

Some significant milestones achieved by Circassia Group PLC include the successful completion of Phase III clinical trials for its respiratory disease products, the establishment of strategic partnerships with leading pharmaceutical companies, and the launch of several innovative treatments in multiple markets. Circassia Group PLC has also been granted regulatory approvals for its products in key markets, further contributing to its growth and market presence. The company continues to invest in research and development to bring advanced therapies to patients, solidifying its position as a prominent player in the healthcare industry.

Circassia Group PLC is a pharmaceutical company specializing in the development and commercialization of innovative allergy and respiratory products. Established in 2006, Circassia has been dedicated to improving the lives of patients suffering from various respiratory conditions. With a strong emphasis on research and development, the company has successfully delivered breakthrough treatments using its proprietary technologies. Circassia's mission is to provide effective and safe solutions for respiratory diseases, including allergic rhinitis and asthma. With a focus on improving patients' quality of life, Circassia Group PLC continues to expand its portfolio and explore new opportunities in the field of respiratory medicine.

The main competitors of Circassia Group PLC in the market include pharmaceutical companies such as GlaxoSmithKline, AstraZeneca, and Teva Pharmaceuticals.

Circassia Group PLC is primarily active in the healthcare and pharmaceutical industries. The company focuses on developing and commercializing innovative products for the treatment of respiratory diseases and allergies. Circassia aims to improve the lives of patients by addressing unmet medical needs through its expertise in immunology and respiratory science. With a strong portfolio of products, Circassia is dedicated to providing effective solutions and enhancing patient care in these critical industries.

The business model of Circassia Group PLC revolves around the development, commercialization, and sale of innovative specialty pharmaceutical products. Circassia focuses on the treatment of respiratory diseases, particularly asthma and chronic obstructive pulmonary disease (COPD). Through its advanced technology and expertise, Circassia aims to improve patient outcomes and enhance the quality of respiratory care. With a strong portfolio of products, the company is committed to enhancing treatment options and addressing unmet medical needs. Circassia Group PLC strives to make a significant impact on respiratory health globally.

Rasio P/E Niox Group adalah 29,42.

Rasio KUV dari Niox Group adalah 7,02.

Skor Kualitas AlleAktien untuk Niox Group adalah 3/10.

Omset diharapkan Niox Group adalah 42,85 Juta. GBP.

Laba diharapkan Niox Group adalah 10,23 Juta. GBP.

The Circassia Group PLC is a biopharmaceutical company that specializes in the development and marketing of products for the treatment of respiratory diseases and allergies. The company was founded in 2006 and is headquartered in Oxford, United Kingdom. The business activities of Circassia Group PLC are divided into two divisions: the respiratory division and the allergology division. In the respiratory division, the company develops therapies and medications for the treatment of asthma, chronic obstructive pulmonary disease (COPD), and other respiratory diseases. The allergology division focuses on the treatment of allergies, including hay fever and food allergies. One of Circassia's key innovations in the respiratory division is the NIOX system, which allows for non-invasive measurement of inflammation markers in the breath. This enables more precise determination of the severity of respiratory diseases such as asthma, improving treatment and disease control. The company also offers the Tudorza Pressair inhalation device for the treatment of COPD patients. In the allergology division, Circassia has developed a portfolio of immunotherapeutic treatments for a variety of allergies, including grass pollen, tree pollen, and house dust mites. The company has also partnered with Anergis to develop a therapy for food allergies. Circassia Group PLC's business strategy focuses on product and therapy innovation. The company invests heavily in research and development to develop new and more effective treatments for respiratory and allergy diseases. Circassia has a team of experienced scientists and clinicians who work closely together to ensure that the company's products meet the highest clinical standards. Circassia Group PLC is also expanding globally and has partnerships and distribution agreements with companies in Asia, Europe, and North America. The company has an international distribution network that ensures access to its products in key markets worldwide. The revenue of Circassia Group PLC primarily comes from the sale of products, including NIOX and Tudorza Pressair. The company has also entered into a number of licensing agreements that allow for the use of technologies and products in new markets and indications. Overall, Circassia Group PLC is a leading company in the development of products for the treatment of respiratory and allergy diseases. Through a combination of innovation and expansion strategy, the company has built a strong presence in key markets and is expected to continue to grow and expand.

Niox Group membayarkan dividen sebesar 0 GBP yang dibagi melalui pembayaran dalam setahun.

Dividen untuk Niox Group saat ini tidak dapat dihitung atau perusahaan tidak membagikan dividen.

ISIN dari Niox Group adalah GB00BJVD3B28.

WKN dari Niox Group adalah A1XFBM.

Ticker dari Niox Group adalah NIOX.L.

Dalam 12 bulan terakhir, Niox Group membayar dividen sebesar 0,03 GBP . Ini setara dengan yield dividen sekitar 3,73 %. Untuk 12 bulan mendatang, Niox Group diperkirakan akan membayar dividen sebesar 0,03 GBP.

Imbal hasil dividen dari Niox Group saat ini adalah 3,73 %.

Niox Group membayar dividen setiap kuartal. Dividen ini dibayarkan pada bulan .

Niox Group membayar dividen setiap tahun dalam 0 tahun terakhir.

Untuk 12 bulan ke depan, diperkirakan akan ada dividen sebesar 0,03 GBP. Ini setara dengan yield dividen sebesar 3,73 %.

Niox Group dikelompokkan dalam sektor 'Kesehatan'.

Untuk menerima dividen terakhir dari Niox Group tanggal 24/6/2024 sejumlah 0,01 GBP, Anda harus memiliki saham tersebut di portofolio sebelum tanggal Ex-Tag pada 23/5/2024.

Pembayaran dividen terakhir dilakukan pada 24/6/2024.

Pada tahun 2023, Niox Group 0 GBP telah dibayarkan sebagai dividen.

Dividen dari Niox Group dibayarkan dalam GBP.